Continuing Education Activity

Waardenburg syndrome comprises a group of genetic disorders resulting from mutations in genes that impair the migration and differentiation of neural crest cells. This condition typically presents with varying degrees of congenital sensorineural hearing loss and pigmentary abnormalities of the skin, hair, and eyes. Waardenburg syndrome is classified into 4 types, each distinguished by specific clinical features and underlying genetic mutations. A positive family history is the primary risk factor, reflecting the autosomal dominant or, less commonly, autosomal recessive inheritance patterns associated with different subtypes. Diagnosis is primarily based on clinical evaluation, supported by audiological assessments and, when available, molecular genetic testing. Management emphasizes early hearing rehabilitation, regular ophthalmological monitoring, and cosmetic support for pigmentation abnormalities. Prognosis varies based on the specific type and severity of the condition; however, with appropriate intervention, most individuals maintain normal life expectancy and developmental potential.

This activity focuses on recognizing and managing Waardenburg syndrome by reviewing its genetics, risk factors, pathophysiology, and clinical features. This activity provides practical insights into early identification, diagnostic approaches, and comprehensive management strategies, while emphasizing best practices in diagnosis and treatment. Additionally, this activity underscores the importance of interprofessional collaboration among healthcare providers in enhancing coordinated care and improving outcomes for affected individuals.

Objectives:

• Identify the genetic basis, inheritance patterns, and hallmark clinical features of Waardenburg syndrome.
• Implement early audiologic assessments, including audiograms and auditory brainstem response tests, in suspected cases.
• Apply current best practices for managing associated complications, including sensorineural hearing loss and Hirschsprung disease.
• Collaborate with the interprofessional healthcare team to ensure multidisciplinary care that supports developmental, psychosocial, and quality-of-life outcomes.

Introduction

Waardenburg syndrome encompasses a group of genetic disorders, most commonly inherited in an autosomal dominant pattern. The syndrome is named after Dutch ophthalmologist and geneticist Petrus Johannes Waardenburg, who first described it in 1951.[1] Pathogenic mutations disrupt the migration and proliferation of neural crest cells during embryogenesis. Because melanocytes develop from the neural crest, individuals affected by this condition exhibit abnormal melanocyte distribution, resulting in patchy depigmentation.

This rare disorder involves loss of pigment-producing cells in the eyes, skin, hair, and the stria vascularis of the cochlea.[2] Clinical presentation varies, but hallmark features include a broad nasal root, hypertelorism with dystopia of the lacrimal puncta, heterochromia or hypopigmented irides, medial eyebrow hypertrichosis, a white forelock, and congenital sensorineural hearing loss (SNHL).[3]

Although no curative treatment is available, supportive care may include cochlear implantation and surgical management of associated conditions, such as Hirschsprung disease. Genetic counseling has a key role in facilitating early diagnosis, risk assessment, and informed family planning.[4]

Etiology

Waardenburg syndrome is most often inherited in an autosomal dominant pattern. Various gene mutations—including insertions, deletions, frameshifts, missense, and nonsense variants—interfere with neural crest cell migration and differentiation during embryogenesis, leading to the characteristic clinical features of the syndrome.[5] Penetrance and expressivity vary depending on the specific gene involved.

A total of 4 clinical subtypes of Waardenburg syndrome have been identified, as mentioned below.

• Type 1, one of the most common forms, results from mutations in the PAX3 gene and is typically characterized by congenital SNHL, dystopia canthorum (lateral displacement of the inner canthi), neural tube defects, cleft lip or palate, and patchy depigmentation of the skin and hair.[6] Ocular pigmentary abnormalities also frequently accompany these features.
• Type 2, another common form, arises from mutations in the MITF gene.[7] Unlike type 1, individuals with type 2 do not exhibit dystopia canthorum but share other clinical features.
• Type 3 is considered a more severe variant of type 1 and includes additional musculoskeletal abnormalities, particularly affecting the upper limbs.[8]
• Type 4 is typically inherited in an autosomal recessive manner and is caused by mutations in EDNRB or EDN3, which encode endothelin receptor type B and endothelin-3, respectively. This subtype may be associated with Hirschsprung disease due to involvement of the enteric nervous system.[9]

Epidemiology

The prevalence of Waardenburg syndrome varies geographically. In the Netherlands, the estimated incidence is approximately 1 in 212,000 individuals, with low penetrance observed in about 20% of cases. Globally, the estimated prevalence is approximately 1 in 42,000 individuals. Types 1 and 2 of Waardenburg syndrome are the most frequently reported subtypes worldwide, whereas type 3 remains exceedingly rare.[10] Type 4 accounts for approximately 19% of all reported cases.[11]

Among individuals with deaf-mutism, Waardenburg syndrome occurs in 0.9% to 2.8%. The condition affects all racial and ethnic groups equally and demonstrates no sex predilection. Although diagnosis is often made at birth based on characteristic physical features, some pigmentary changes may become more apparent with age.

Pathophysiology

Waardenburg syndrome is a genetic disorder most commonly inherited in an autosomal dominant pattern. Several hypotheses have been proposed to explain its pathogenesis and the variability among clinical subtypes. The most widely accepted explanation is the neural crest theory, which attributes the disorder to abnormalities in the differentiation and migration of neural crest cells during embryogenesis. This theory also accounts for the association between Waardenburg syndrome and Hirschsprung disease, as both conditions involve disrupted development of neural crest cells. First arch syndrome, resulting from the failure of neural crest cells to migrate into the first pharyngeal arch, shares overlapping clinical features with Waardenburg syndrome.[12][13]

Type 1 Waardenburg syndrome

In type 1 Waardenburg syndrome, mutations occur in the PAX3 gene, located on chromosome 2q36.1. The PAX3 gene encodes a transcription factor that primarily functions as a transcriptional activator but may also act as a repressor for specific target genes.[14] During embryonic development, PAX3 is expressed in progenitor cells that contribute to the formation of skeletal muscle, the nervous system, and the lateral margins of the neural plate—regions that give rise to neural crest cells.[15][16] As development progresses, PAX3 expression emerges in melanoblasts, Schwann cell precursors, and structures of the inner ear and mandible. Additionally, translation of this gene is crucial in defining the location of the nasion.[16][17]

Type 2 Waardenburg syndrome

In type 2 Waardenburg syndrome, mutations affect the MITF gene located on chromosome 3p13. This gene encodes a transcription factor expressed in melanocytes, osteoclasts, and mast cells.[18] The MITF protein is essential for melanin production, DNA repair, mitotic regulation, membrane trafficking, and mitochondrial function. These diverse roles account for the pigmentation abnormalities and SNHL observed in type 2 Waardenburg syndrome, as well as its involvement in other conditions, such as Tietze syndrome and melanoma.[19][20][21]

Type 3 Waardenburg syndrome

Type 3 Waardenburg syndrome, the rarest variant, results from mutations in the PAX3 gene, similar to those in type 1.[22] Diagnosis is clinical and based on characteristic features of hypopigmentation and SNHL in combination with limb anomalies.[23] Upper limb involvement is more common and may include hypoplasia and flexion contractures. Homozygous PAX3 mutations are typically associated with more severe musculoskeletal manifestations than heterozygous mutations.[24] Type 3 is also referred to as Klein-Waardenburg syndrome.[25]

Type 4 Waardenburg syndrome

Type 4 Waardenburg syndrome combines the classic pigmentary abnormalities and SNHL, which are characteristic of Waardenburg syndrome, with aganglionic megacolon, and is consistent with Hirschsprung disease.[26] This subtype, also known as Waardenburg-Hirschsprung syndrome or Waardenburg-Shah syndrome, includes 3 genetically distinct forms.[27]

• Type 4A results from mutations in the EDNRB gene located on chromosome 13q22.3, which encodes the endothelin B receptor.[28]
• Type 4B involves mutations in the EDN3 gene located on chromosome 20q13.32, which encodes an endothelin receptor ligand.
• Type 4C arises from mutations in the SOX10 gene located on chromosome 22q13.1, which encodes a transcription factor critical for neural crest development.[29]

Individuals with heterozygous mutations in types 4A and 4B may be asymptomatic or exhibit only mild clinical features. In contrast, truncating mutations in SOX10, associated with type 4C, often result in more severe clinical phenotypes and are frequently accompanied by additional neurological abnormalities.[30]

Several etiological theories have been proposed to explain Waardenburg syndrome, including intrauterine necrosis and associations with status dysraphicus; however, none fully account for its diverse clinical features. Inherited forms of deafness contribute to approximately 50% of congenital hearing loss, with about 70% of these cases involving mutations in single genes that directly impair auditory function. Syndromic forms of deafness, including that seen in Waardenburg syndrome, are often associated with additional developmental anomalies. In Waardenburg syndrome, hearing loss is typically caused by mutations in the MITF gene in type 2 and the PAX3 gene in type 1. Type 4 involves mutations in genes encoding the endothelin B receptor (EDNRB) or its ligand, endothelin 3 (EDN3).

Histopathology

The characteristic histopathological feature of Waardenburg syndrome is the absence or severe reduction of melanocytes, although residual dihydroxyphenylalanine-positive cells may be present. In hypopigmented skin, melanosomes or indeterminate dendritic cells can be observed within keratinocytes. Langerhans cells in the epidermis appear normal. The density of pigment cells is reduced at the margins of depigmented areas, which is often accompanied by nuclear and cytoplasmic abnormalities. Vacuolated cells may display a clear halo surrounded by melanosomes.[31] Histopathological examination of the inner ear at autopsy reveals spiral ganglion atrophy and a reduction in nerve fibers, accompanied by the absence of the organ of Corti.[32]

History and Physical

Clinically, Waardenburg syndrome is often identified by characteristic morphological features that manifest after birth. A detailed physical examination and comprehensive family history form the foundation of the diagnostic evaluation. Typical features include a white forelock, broad nasal root, and heterochromia irides (differences in eye color). Some children may fail initial newborn hearing screening, if conducted, whereas others may raise concerns later due to a lack of auditory responsiveness. Not all individuals with Waardenburg syndrome exhibit every clinical feature. Based on genetic mutations and clinical presentation, 4 distinct types of Waardenburg syndrome have been described.

• Type 1 is characterized by dystopia canthorum, a broad nasal root, a short philtrum, and a short retropositional maxilla.
• Type 2 presents with normally positioned canthi, SNHL, and heterochromia irides.
• Type 3, also known as Klein-Waardenburg syndrome, shares features with type 1, but includes prominent musculoskeletal abnormalities, such as underdeveloped carpal bones, aplasia of the first and second ribs, sacral cysts, limb anomalies, and muscle hypoplasia with syndactyly. In some cases, type 3 includes the full spectrum of primary features along with severe skeletal deformities, microcephaly, and intellectual disability.
• Type 4, also known as Waardenburg-Shah syndrome, resembles type 2 clinically but is distinguished by the presence of congenital aganglionic megacolon consistent with Hirschsprung disease.

Pigmentary changes in Waardenburg syndrome involve the skin, hair, and eyes. Skin manifestations may include achromic patches and hyperpigmented macules superimposed on normally pigmented areas. Ocular abnormalities commonly feature heterochromia iridis or bilateral isohypochromia. Diagnosis is primarily clinical and guided by established major and minor criteria (see Table below).[33] A clinical diagnosis of type 1 Waardenburg syndrome requires the presence of either 2  major criteria or 1 major and 2 minor criteria.[34]

Table

Table. Major and Minor Diagnostic Criteria for Waardenburg Syndrome.

Evaluation

Types 1 and 3 Waardenburg syndrome are the most common variants. The point mutations responsible can be detected using multiplex ligation-dependent probe amplification targeting specific genes. Formal measurements of interpupillary and intercanthal distances should be taken and compared with normative charts when there is uncertainty in distinguishing hypertelorism from telecanthus. A comprehensive audiogram is essential, and depending on the patient’s age, auditory brainstem response testing may provide the most accurate assessment of hearing.[35]

No specific radiological tests are recommended for evaluating Waardenburg syndrome. However, imaging of the middle ear structures and cochlea may be necessary, depending on the clinical presentation and genetic findings. High-resolution computed tomography (CT) or, in some cases, magnetic resonance imaging (MRI) can be used when imaging is warranted.[36]

Treatment / Management

Waardenburg syndrome is a genetic disorder without a definitive treatment.[37] Early identification and intervention for hearing impairments in affected children are crucial to support optimal language development, comprehension, and social integration. Hearing aids may be beneficial depending on the severity of hearing loss, while cochlear implantation is often required for congenital deafness. Sun protection is recommended for hypopigmented skin patches due to their increased susceptibility to UV damage.[38] Genetic counseling is a critical component in the care of individuals with this condition.

Differential Diagnosis

Several conditions may present with overlapping features and should be considered in the differential diagnosis of Waardenburg syndrome. These disorders often involve pigmentary changes, auditory abnormalities, or other systemic manifestations that require careful clinical distinction.

• Piebaldism: A genetic disorder characterized by congenital depigmentation of the skin and hair, typically presenting with a stable, nonprogressive course. Please see StatPearls' companion resource, "Piebaldism," for more information.
• Tietze syndrome: A rare genetic disorder characterized by profound congenital deafness and generalized hypopigmentation. Musculoskeletal abnormalities may also be present.
• Oculocutaneous albinism: A group of genetic disorders resulting from impaired melanin synthesis, leading to diffuse depigmentation of the skin, hair, and eyes.
• Vogt-Koyanagi-Harada disease: An autoimmune condition affecting the skin, eyes, inner ear, and central nervous system, often presenting with uveitis, vitiligo, and hearing loss.
• Vitiligo: An acquired condition that presents with progressive depigmented macules on the skin and, occasionally, hair.

Accurate diagnosis relies on a detailed clinical history, physical examination, and genetic testing when appropriate. Differentiating Waardenburg syndrome from these conditions is essential for guiding management, prognosis, and genetic counseling.

Prognosis

Waardenburg syndrome is a chronic condition; however, individuals affected by this condition typically have a normal life expectancy. Morbidity stems from abnormalities in neural crest–derived tissues and may include intellectual disability, deafness, ocular disorders such as cataracts, skeletal anomalies, and psychiatric conditions.[39] These clinical features reflect the underlying genetic mutations causing the disease. Homozygous mutations often lead to more severe manifestations than heterozygous mutations, with certain variants, particularly type 4, generally associated with greater severity

Complications

The complications of Waardenburg syndrome vary depending on the subtype. Type 1 may be associated with blepharophimosis, whereas type 2 is commonly characterized by SNHL, which occurs in approximately 70% of cases. Type 3 is distinguished by skeletal anomalies and, in more severe cases, intellectual disability and microcephaly. The primary complication of type 4 is congenital aganglionic megacolon, also known as Hirschsprung disease.[40]

Consultations

Consultation with a geneticist is essential in the management of Waardenburg syndrome, particularly because type 1 follows an autosomal dominant inheritance pattern and often occurs within families. Although prenatal testing can detect pathogenic mutations, it does not reliably predict the severity of clinical manifestations. Effective management requires an interprofessional healthcare team, including audiologists, dermatologists, ophthalmologists, and surgeons, to ensure early intervention and comprehensive care for the syndrome’s multisystem complications.

Deterrence and Patient Education

Life expectancy is generally normal in children with Waardenburg syndrome. Genetic counseling is crucial, as a single affected gene can be passed to future generations. Without a definitive treatment, educating patients and families about symptom-based management is essential. Morbidity arises from defects in neural crest–derived tissues.[41]

Enhancing Healthcare Team Outcomes

Waardenburg syndrome presents complex challenges and is best managed by an interprofessional team of healthcare providers capable of addressing its broad spectrum of complications. Psychosocial functioning and quality of life may be significantly impacted, especially when psychiatric conditions coexist. Effective management often involves collaboration among dermatologists, psychiatrists, ophthalmologists, neurologists, and rheumatologists. Dermatology-trained nurses play a crucial role in patient education, support, treatment guidance, and monitoring for complications. Effective communication within the healthcare team is crucial for optimizing patient outcomes.[42]

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Sil A, Panigrahi A. Visual Dermatology: Waardenburg Syndrome Type II. J Cutan Med Surg. 2020 May/Jun;24(3):305. [PubMed: 32421428]

2.

Tan J, Duron A, Sucov HM, Makita T. Placode and neural crest origins of congenital deafness in mouse models of Waardenburg-Shah syndrome. iScience. 2025 Jan 17;28(1):111680. [PMC free article: PMC11762213] [PubMed: 39868048]

3.

Grewal PS, Knight H, Michaelides M. Asymmetric choroidal hypopigmentation in a Son and mother with Waardenburg syndrome type I. Ophthalmic Genet. 2020 Jun;41(3):284-287. [PubMed: 32281454]

4.

Yu Y, Liu W, Chen M, Yang Y, Yang Y, Hong E, Lu J, Zheng J, Ni X, Guo Y, Zhang J. Two novel mutations of PAX3 and SOX10 were characterized as genetic causes of Waardenburg Syndrome. Mol Genet Genomic Med. 2020 May;8(5):e1217. [PMC free article: PMC7216796] [PubMed: 32168437]

5.

Alehabib E, Alinaghi S, Pourfatemi F, Darvish H. Incomplete penetrance of MITF gene c.943C>T mutation in an extended family with Waardenburg syndrome type II. Int J Pediatr Otorhinolaryngol. 2020 Aug;135:110014. [PubMed: 32422366]

6.

Agrawal R, Walia S. Waardenburg Syndrome Type 1. Indian J Ophthalmol. 2022 Jul;70(7):2679-2681. [PMC free article: PMC9426065] [PubMed: 35791202]

7.

Ren SM, Kong XD, Wu QH, Jiao ZH, Chen C, Qin ZB. [Analysis of genetic variation in patients with Waardenburg syndrome type Ⅱ by next generation sequencing]. Zhonghua Yi Xue Za Zhi. 2020 Mar 24;100(11):853-858. [PubMed: 32234158]

8.

Tekin M, Bodurtha JN, Nance WE, Pandya A. Waardenburg syndrome type 3 (Klein-Waardenburg syndrome) segregating with a heterozygous deletion in the paired box domain of PAX3: a simple variant or a true syndrome? Clin Genet. 2001 Oct;60(4):301-4. [PubMed: 11683776]

9.

Chandra Mohan SLN. Case of Waardenburg Shah syndrome in a family with review of literature. J Otol. 2018 Sep;13(3):105-110. [PMC free article: PMC6291636] [PubMed: 30559775]

10.

Apaydin F, Bereketoglu M, Turan O, Hribar K, Maassen MM, Günhan O, Zenner HP, Pfister M. [Waardenburg syndrome. A heterogenic disorder with variable penetrance]. HNO. 2004 Jun;52(6):533-7. [PubMed: 15029423]

11.

Song J, Feng Y, Acke FR, Coucke P, Vleminckx K, Dhooge IJ. Hearing loss in Waardenburg syndrome: a systematic review. Clin Genet. 2016 Apr;89(4):416-425. [PubMed: 26100139]

12.

Li S, Guo M, Ruan B, Liu Y, Cui X, Han W, Li R. A Novel PAX3 Mutation in a Chinese Family with Waardenburg Syndrome Type 1. Genet Test Mol Biomarkers. 2020 May;24(5):249-255. [PubMed: 32250160]

13.

Johnson JM, Moonis G, Green GE, Carmody R, Burbank HN. Syndromes of the first and second branchial arches, part 1: embryology and characteristic defects. AJNR Am J Neuroradiol. 2011 Jan;32(1):14-9. [PMC free article: PMC7964959] [PubMed: 20299437]

14.

Mayanil CS, George D, Freilich L, Miljan EJ, Mania-Farnell B, McLone DG, Bremer EG. Microarray analysis detects novel Pax3 downstream target genes. J Biol Chem. 2001 Dec 28;276(52):49299-309. [PubMed: 11590174]

15.

Buckingham M, Relaix F. The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions. Annu Rev Cell Dev Biol. 2007;23:645-73. [PubMed: 17506689]

16.

Monsoro-Burq AH. PAX transcription factors in neural crest development. Semin Cell Dev Biol. 2015 Aug;44:87-96. [PubMed: 26410165]

17.

Wu M, Li J, Engleka KA, Zhou B, Lu MM, Plotkin JB, Epstein JA. Persistent expression of Pax3 in the neural crest causes cleft palate and defective osteogenesis in mice. J Clin Invest. 2008 Jun;118(6):2076-87. [PMC free article: PMC2381747] [PubMed: 18483623]

18.

Hershey CL, Fisher DE. Mitf and Tfe3: members of a b-HLH-ZIP transcription factor family essential for osteoclast development and function. Bone. 2004 Apr;34(4):689-96. [PubMed: 15050900]

19.

Garraway LA, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer. 2006 Aug;6(8):593-602. [PubMed: 16862190]

20.

Cheli Y, Ohanna M, Ballotti R, Bertolotto C. Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res. 2010 Feb;23(1):27-40. [PubMed: 19995375]

21.

Smith SD, Kelley PM, Kenyon JB, Hoover D. Tietz syndrome (hypopigmentation/deafness) caused by mutation of MITF. J Med Genet. 2000 Jun;37(6):446-8. [PMC free article: PMC1734605] [PubMed: 10851256]

22.

Li S, Qin M, Mao S, Mei L, Cai X, Feng Y, He C, Song J. A comprehensive genotype-phenotype evaluation of eight Chinese probands with Waardenburg syndrome. BMC Med Genomics. 2022 Nov 03;15(1):230. [PMC free article: PMC9632049] [PubMed: 36329483]

23.

Somashekar PH, Upadhyai P, Narayanan DL, Kamath N, Bajaj S, Girisha KM, Shukla A. Phenotypic diversity and genetic complexity of PAX3-related Waardenburg syndrome. Am J Med Genet A. 2020 Dec;182(12):2951-2958. [PubMed: 32990402]

24.

Salah S, Meiner V, Abumayaleh A, Asafra A, Al-Sharif T, Al-Fallah O, Hasasneh B, Zlotogora J. Biallelic variants in PAX3 cause Klein syndrome. Clin Genet. 2022 Sep;102(3):223-227. [PubMed: 35607853]

25.

Saberi M, Golchehre Z, Salmani H, Karamzade A, Tabatabaie SZ, Keramatipour M. First report of Klein-Waardenburg Syndrome in Iran and a novel pathogenic splice site variant in PAX3 gene. Int J Pediatr Otorhinolaryngol. 2018 Oct;113:229-233. [PubMed: 30173992]

26.

Jabeen R, Babar ME, Ahmad J, Awan AR. Novel mutations of endothelin-B receptor gene in Pakistani patients with Waardenburg syndrome. Mol Biol Rep. 2012 Jan;39(1):785-8. [PubMed: 21547364]

27.

Read AP, Newton VE. Waardenburg syndrome. J Med Genet. 1997 Aug;34(8):656-65. [PMC free article: PMC1051028] [PubMed: 9279758]

28.

Pingault V, Ente D, Dastot-Le Moal F, Goossens M, Marlin S, Bondurand N. Review and update of mutations causing Waardenburg syndrome. Hum Mutat. 2010 Apr;31(4):391-406. [PubMed: 20127975]

29.

Fernández RM, Núñez-Ramos R, Enguix-Riego MV, Román-Rodríguez FJ, Galán-Gómez E, Blesa-Sánchez E, Antiñolo G, Núñez-Núñez R, Borrego S. Waardenburg syndrome type 4: report of two new cases caused by SOX10 mutations in Spain. Am J Med Genet A. 2014 Feb;164A(2):542-7. [PubMed: 24311220]

30.

Pingault V, Zerad L, Bertani-Torres W, Bondurand N. SOX10: 20 years of phenotypic plurality and current understanding of its developmental function. J Med Genet. 2022 Feb;59(2):105-114. [PMC free article: PMC8788258] [PubMed: 34667088]

31.

Ez-Zahraoui M, Lezrek O, Cherkaoui O. [Waardenburg syndrome type 1]. J Fr Ophtalmol. 2019 Jan;42(1):94-95. [PubMed: 30554874]

32.

Brizzolara A, Torre M, Favre A, Pini Prato A, Bocciardi R, Martucciello G. Histochemical study of Dom mouse: A model for Waardenburg-Hirschsprung's phenotype. J Pediatr Surg. 2004 Jul;39(7):1098-103. [PubMed: 15213907]

33.

Astakhov YS, Tultseva SN, Lisochkina AB, Takhtaev YV, Astakhov SY, Shakhnazarova AA. [Ophthalmologic manifestations of Waardenburg syndrome]. Vestn Oftalmol. 2019;135(6):91-99. [PubMed: 32015313]

34.

Gowda VK, Srinivas S, Srinivasan VM. Waardenburg Syndrome Type I. Indian J Pediatr. 2020 Mar;87(3):244. [PubMed: 31989460]

35.

Fan W, Ni K, Chen F, Li X. Hearing characteristics and cochlear implant effects in children with Waardenburg syndrome: a case series. Transl Pediatr. 2022 Jul;11(7):1234-1241. [PMC free article: PMC9360812] [PubMed: 35958009]

36.

Kontorinis G, Goetz F, Lanfermann H, Luytenski S, Giesemann AM. Inner ear anatomy in Waardenburg syndrome: radiological assessment and comparison with normative data. Int J Pediatr Otorhinolaryngol. 2014 Aug;78(8):1320-6. [PubMed: 24882458]

37.

Ren S, Chen X, Kong X, Chen Y, Wu Q, Jiao Z, Shi H. Identification of six novel variants in Waardenburg syndrome type II by next-generation sequencing. Mol Genet Genomic Med. 2020 Mar;8(3):e1128. [PMC free article: PMC7057110] [PubMed: 31960627]

38.

Wallis KE, Blum NJ, Waryasz SA, Augustyn M. Bilateral Cochlear Implants: Maximizing Expected Outcomes. J Dev Behav Pediatr. 2018 Feb/Mar;39(2):177-179. [PubMed: 29324475]

39.

Minami SB, Nara K, Mutai H, Morimoto N, Sakamoto H, Takiguchi T, Kaga K, Matsunaga T. A clinical and genetic study of 16 Japanese families with Waardenburg syndrome. Gene. 2019 Jul 01;704:86-90. [PubMed: 30978479]

40.

Raissi D, Christie A, Applegate K. Waardenburg Syndrome and Left Persistent Superior Vena Cava. J Clin Imaging Sci. 2018;8:44. [PMC free article: PMC6251238] [PubMed: 30546928]

41.

Boutkhil M, Benchekroun Belabess S, El Ikhloufi M, Taouri N, Cherkaoui O. [Waardenburg syndrome, a family story]. J Fr Ophtalmol. 2019 Sep;42(7):e319-e324. [PubMed: 31130388]

42.

Shrinkhal, Singh A, Mittal SK, Agrawal A, Verma R, Yadav P. Waardenburg syndrome with dry eyes: A rare association. Taiwan J Ophthalmol. 2019 Jul-Sep;9(3):198-201. [PMC free article: PMC6759548] [PubMed: 31572658]

Disclosure: Ryan Winters declares no relevant financial relationships with ineligible companies.

Disclosure: Sadia Masood declares no relevant financial relationships with ineligible companies.